Molecure targets 50 patients: Molecure stock has PLN 156.3 million value

Published on 10/18/2026 at 12:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The 43-patient trial count gives Molecure stock a clinical marker as of early October 2026. Results are due October 30, 2026.

Clinical milestones and cash

Molecure targeted 50 randomized patients for its next OATD-01 analysis on October 5, 2026.
Operating revenue fell to PLN 1.86 million in the first half of 2026 from PLN 3.52 million.
Molecure scheduled its third-quarter report for October 30, 2026, followed by BIO Europe from November 9 to November 11, 2026.

Molecure, PLONCTH00011, Illustration mit AI erstellt.

Molecure (PLONCTH00011) is targeting 50 randomized patients for the next interim analysis of its OATD-01 trial, according to Bankier.pl on October 5, 2026. The company had 43 randomized patients at the beginning of October, while the next analysis is planned for the second quarter of 2027.

The 50-patient threshold

The threshold matters because Molecure intends to use the second interim analysis to assess safety, efficacy and the required final sample size. The original KITE trial design calls for 96 patients, so a lower number could reduce both duration and cost, although the company has not presented a final revised target.

Molecure said on September 30, 2026, that the KITE study had reached 30 patients during the first half of 2026 and that an independent committee had recommended continuing the trial in July 2026 without protocol changes.

Three milestones with figures

The financial picture remains tied to clinical execution. Operating revenue fell to PLN 1.86 million in the first half of 2026 from PLN 3.52 million in the first half of 2025, while net loss narrowed to PLN 6.31 million from PLN 8.52 million, according to Molecure.

Cash stood at PLN 24.91 million on June 30, 2026, compared with PLN 16.35 million at the end of 2025. The company also said it had received more than PLN 27 million in grants for its artificial-intelligence platform, including PLN 14 million allocated for 2026 and 2027.

What comes next for funding?

The company expects the second OATD-01 analysis in the second quarter of 2027, while its cash runway extends into the first half of 2027, as Bankier.pl reported on October 5, 2026. Management is considering partnering income, grants, debt and a possible share issue to finance later development.

The next scheduled company date is October 30, 2026, when Molecure plans to publish its third-quarter 2026 report. The investor calendar also lists BIO Europe from November 9 to November 11, 2026, according to the Molecure investor calendar.

Market value and clinical risk

Molecure had a market capitalization of PLN 156.3 million as of October 16, 2026. That valuation leaves clinical progress, patient recruitment and financing capacity closely linked in the investment case.

The further course of trading is shown by the continuously updated real-time quote of Molecure stock.